ANXA1 is useful as a prognostic biomarker in lower grade glioma patients with MGMT promoter methylation [36] and a prognostic indicator and an immunotherapy marker for the tumour microenvironment in glioma [37]. This evidence concerns the gene MGMT and central nervous system cancer.